Latest research on Pemetrexed

Pemetrexed (brand name Alimta) is a chemotherapy drug manufactured and marketed by Eli Lilly and Company. Its indications are the treatment of pleural mesothelioma as well as non-small cell lung cancer.

Latest findings

In particular, Pemetrexed with Cisplatin has demonstrated superior median overall survival, response rate, lung function and quality-of-life measures in the largest randomised trial in MPM. [source, 2003]
His only past medical history of note was a left malignant pleural mesothelioma for which he had completed six cycles of Pemetrexed and Cisplatin chemotherapy one year previously. [source]
The lung cancer was managed with two cycles of neoadjuvant chemotherapy (Cisplatin and Pemetrexed) followed by surgical resection. [source]
Treatment was switched to Pemetrexed and bevacizumab. [source]
Later, when his disease progressed on Erlotinib, we decided to give Pemetrexed with bevacizumab as subsequent therapy. [source]